Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

52.41 +1.46 (+2.87%)
Official Closing Price Updated: 7:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
90 91 Next >
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits
Hims & Hers faces stock pressure after Novo Nordisk ends Wegovy access, citing compounding violations and marketing concerns. 
Via Benzinga
Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: 'Coverage Is Not The Same As Access,' Says Expert
Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access. 
Via Benzinga
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
Via The Motley Fool
2 Stocks to Buy on the Dip and Hold for 10 Years
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Is Hims & Hers Stock in Trouble?
Via The Motley Fool
Topics Supply Chain
Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report
Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound. 
Via Benzinga
Amazon Wants More Power
Amazon's latest data center will reportedly require the same amount of electricity as 1 million homes. 
Via The Motley Fool
Topics Artificial Intelligence
Got $200? 2 Biotech Stocks to Buy and Hold Forever
Via The Motley Fool
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
Circle Internet, Hims & Hers Health And CoreWeave Are Among Top 10 Large Cap Losers Last Week (June 23-27): Are The Others In Your Portfolio?
Last week's worst performers include CRCL, HIMS, VG, QXO, CRWV, DUOL, EQIX, EQNR, CF, and EC. Are they in your portfolio? 
Via Benzinga
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value 
Via MarketBeat
Topics Artificial Intelligence Economy
Benzinga Bulls And Bears: Nvidia, Micron, HIMS — And Markets Soar On Mideast And Tariff Relief
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs
MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations. 
Via Benzinga
Elon Musk Backs Satya Nadella's View That AI Must Produce 'Socially Useful' Results: 'The Real Question In The Next Five Years Is...'
Tesla (NASDAQ: TSLA) CEO Elon Musk endorsed Microsoft (NASDAQ: MSFT) Satya Nadella's perspective on the practical impact of AI, emphasizing its benefits to sectors like healthcare, education, and... 
Via Benzinga
Topics Artificial Intelligence
Hims & Hers Stock Tumbles as Novo Nordisk Ends Its Wegovy Sales Deal. Can the Telehealth Giant Recover?
The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies. 
Via The Motley Fool
Topics Intellectual Property
Massive News for Hims & Hers Stock Investors!
Via The Motley Fool
GLP-1 Showdown In India: Eli Lilly’s Mounjaro Pen Approved Just Days After Novo’s Wegovy Launch
Local drugmakers, including Sun Pharma, Biocon, Zydus, Cipla, and Dr. Reddy’s are racing to develop cheaper versions of semaglutide as its Indian patent nears expiry. 
Via Stocktwits
Topics Intellectual Property
This Weight Loss Partnership Was a Short One
Via The Motley Fool
Topics Economy
Why Hims & Hers Stock Is Crashing, and Is It a Buying Opportunity?
Via The Motley Fool
Why Shares in Novo Nordisk Lost Weight Today
Via The Motley Fool
US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows
GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only 8.1% stayed on therapy for three years. 
Via Benzinga
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Novo Nordisk A/S (NVO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Abbott, Dexcom Draw Retail Buzz As RFK Jr. Urges Americans To Embrace Health Wearables
Retail sentiment surged on Stocktwits, with message volume jumping 1,600% for Abbott and 750% for Dexcom. 
Via Stocktwits
Hims & Hers CEO Says 'No Way In Hell We're Gonna Cave On' Selling Compounded Obesity Drugs After Novo Nordisk Breakup
Truist warned that Hims faces renewed litigation risk after Novo's exit, which could create a prolonged legal overhang on the stock. 
Via Stocktwits
Topics Law Enforcement Lawsuit
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
HIMS Crashes On Novo GLP-1 Fallout: Buy The Dip Or Bail?
Telehealth company Hims & Hers (HIMS) saw a 34% stock drop after Novo Nordisk (NVO) ended their relationship. Investors must decide if it's a buying opportunity or a warning sign for the industry. 
Via Benzinga
Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly
Novo Nordisk launches Wegovy in India, pricing it close to Eli Lilly's Mounjaro, while advancing global regulatory efforts for its GLP-1 portfolio. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
90 91 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS